Climb Bio, Inc.
CLYM
$16.33
$1.6010.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.62% | 2.58% | 28.78% | 5.95% | 11.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.85% | -33.92% | 155.47% | 26.93% | 126.54% |
| Operating Income | -43.85% | 33.92% | -155.47% | -26.93% | -126.54% |
| Income Before Tax | -55.76% | 33.97% | -108.13% | -44.89% | 84.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.76% | 33.97% | -108.13% | -44.89% | 84.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.76% | 33.97% | -108.13% | -44.89% | 84.21% |
| EBIT | -43.85% | 33.92% | -155.47% | -26.93% | -126.54% |
| EBITDA | -43.80% | -- | -- | -- | -- |
| EPS Basic | -38.22% | 34.68% | -100.00% | -42.80% | 92.91% |
| Normalized Basic EPS | -38.33% | 34.70% | -232.99% | -42.77% | -20.45% |
| EPS Diluted | -38.22% | 34.68% | -100.00% | -42.80% | 92.91% |
| Normalized Diluted EPS | -38.33% | 34.70% | -232.99% | -42.77% | -20.45% |
| Average Basic Shares Outstanding | 12.68% | 1.10% | 4.06% | 1.48% | 122.69% |
| Average Diluted Shares Outstanding | 12.68% | 1.10% | 4.06% | 1.48% | 122.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |